Legend Biotech Corporation (LEGN): a likely value trap?

Avoid — a multi-year 77% collapse in a biotech with negative profit margins signals a broken growth story, not a bargain.

⚠ TRAP Fundamentals66/100

Down 77% from its all-time high of $76.50 — now $17.67

Why LEGN dropped

Search tools were unavailable to confirm the exact catalyst, but the stock has been on the floor for over two years since its 2023 peak, well past any single-event crash, which typically means the market has structurally repriced the company's Carvykti (CAR-T therapy) growth and competitive outlook downward rather than reacting to a temporary shock.

Fwd P/E 16.8Op margin 14.9%Rev growth 51.9%Debt/equity 22.6%Analyst upside 174.4%

How this scored 66/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Loss-making today, but operations are profitable (14.9%) and analysts expect positive earnings next year

✅ Generates cash Free cash flow $27M

✅ Not drowning in debt Debt/equity 22.6% (limit 200%)

✅ Can pay its bills Current ratio 3.0 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 5/25

Operating margin 14.9% 5/9

Net profit margin -7.2% 0/8

Return on equity -8.1% 0/8

Growth Is it getting bigger, or dying? 19/25

Revenue growth 51.9% 9/9

Earnings growth unknown 2/8

Expected profit change 310.0% 8/8

Value Is it cheap right now? 17/25

Forward P/E 16.8 7/10

PEG ratio unknown 2/8

Analyst target upside 174.4% 7/7

Balance sheet Will it survive? 25/25

Debt / equity 22.6% 10/10

Current ratio 3.0 8/8

Free cash flow $27M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for LEGN — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-09-16. Research only — not financial advice.